Kura Oncology Inc
Kura Oncology Inc logo
KURA

Kura Oncology Inc (KURA)

$12.574.41%

Market is closed
– opens on 8 PM, 09 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Performance

$12.55
Day's Range
$13.15
$10.41
52-Week Range
$19.93
1 month return5.45%
3 month return6.89%
1 year return5.06%
5 year return33.84%

Insights on Kura Oncology Inc

  • Vs VRTX

    In the last 1 year, Vertex Pharmaceuticals, Inc. has given 26.3% return, outperforming this stock by 27.0%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 28.5% return, outperforming this stock by 17.9%

Highlights

Market Capitalization911.1M
Book Value$6.27
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.99
PEG Ratio0.0
Wall Street Target Price31.5

Company Financials

  • Annual
  • Quarterly

Analyst Recommendation

based on 16 analysts ratings

Buy
93%
Buy
6%
Hold
0%
Sell

Based on 16 Wall street analysts offering stock ratings for Kura Oncology Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 150.6%

Current

$12.57

Target

$31.5

Recommendation Trend

Based on 16 analyst

Current1M Ago3M Ago
Buy
15
8
15
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)2.1
Enterprise Value458.6M
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda-3.4

Technicals

Beta0.83
50 Day MA13.57
200 Day MA14.53

Institutional Holdings

EcoR1 Capital, LLC

9.72%

BlackRock Inc

7.14%

State Street Corporation

6.4%

Suvretta Capital Management, LLC

5.95%

venBio Select Advisor LLC

5.16%

Holocene Advisors, LP

5.09%

Company Information

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology
OrganizationKura Oncology Inc
Employees127
CEODr. Troy Edward Wilson J.D., Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Kura Oncology Inc share price today?

Can Indians buy Kura Oncology Inc shares?

How can I buy Kura Oncology Inc shares from India?

Can Fractional shares of Kura Oncology Inc be purchased?

What are the documents required to start investing in Kura Oncology Inc stocks?

What are today’s High and Low prices of Kura Oncology Inc?

What are today’s traded volumes of Kura Oncology Inc?

What is today’s market capitalisation of Kura Oncology Inc?

What is the 52 Week High and Low Range of Kura Oncology Inc?

How much percentage Kura Oncology Inc is down from its 52 Week High?

How much percentage Kura Oncology Inc is up from its 52 Week low?

What are the historical returns of Kura Oncology Inc?

Who is the Chief Executive Officer (CEO) of Kura Oncology Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*